555 related articles for article (PubMed ID: 32545617)
1. Drugs Commonly Applied to Kidney Patients May Compromise Renal Tubular Uremic Toxins Excretion.
Mihaila SM; Faria J; Stefens MFJ; Stamatialis D; Verhaar MC; Gerritsen KGF; Masereeuw R
Toxins (Basel); 2020 Jun; 12(6):. PubMed ID: 32545617
[TBL] [Abstract][Full Text] [Related]
2. The kidney and uremic toxin removal: glomerulus or tubule?
Masereeuw R; Mutsaers HA; Toyohara T; Abe T; Jhawar S; Sweet DH; Lowenstein J
Semin Nephrol; 2014 Mar; 34(2):191-208. PubMed ID: 24780473
[TBL] [Abstract][Full Text] [Related]
3. Disposition and clinical implications of protein-bound uremic toxins.
Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
[TBL] [Abstract][Full Text] [Related]
4. Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions.
Severin MJ; Hazelhoff MH; Bulacio RP; Mamprin ME; Brandoni A; Torres AM
Nephrology (Carlton); 2017 Aug; 22(8):642-648. PubMed ID: 27282888
[TBL] [Abstract][Full Text] [Related]
5. Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease.
Bush KT; Singh P; Nigam SK
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271169
[TBL] [Abstract][Full Text] [Related]
6. Characterization of uremic toxin transport by organic anion transporters in the kidney.
Deguchi T; Kusuhara H; Takadate A; Endou H; Otagiri M; Sugiyama Y
Kidney Int; 2004 Jan; 65(1):162-74. PubMed ID: 14675047
[TBL] [Abstract][Full Text] [Related]
7. Protein-Bound Uremic Toxins in Hemodialysis Patients Relate to Residual Kidney Function, Are Not Influenced by Convective Transport, and Do Not Relate to Outcome.
van Gelder MK; Middel IR; Vernooij RWM; Bots ML; Verhaar MC; Masereeuw R; Grooteman MP; Nubé MJ; van den Dorpel MA; Blankestijn PJ; Rookmaaker MB; Gerritsen KGF
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32272776
[TBL] [Abstract][Full Text] [Related]
8. Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3.
Hsueh CH; Yoshida K; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
Mol Pharm; 2016 Sep; 13(9):3130-40. PubMed ID: 27467266
[TBL] [Abstract][Full Text] [Related]
9. JBP485 improves gentamicin-induced acute renal failure by regulating the expression and function of Oat1 and Oat3 in rats.
Guo X; Meng Q; Liu Q; Wang C; Sun H; Peng J; Ma X; Kaku T; Liu K
Toxicol Appl Pharmacol; 2013 Sep; 271(2):285-95. PubMed ID: 23707770
[TBL] [Abstract][Full Text] [Related]
10. Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes.
Wu W; Bush KT; Nigam SK
Sci Rep; 2017 Jul; 7(1):4939. PubMed ID: 28694431
[TBL] [Abstract][Full Text] [Related]
11. Association between Protein-Bound Uremic Toxins and Asymptomatic Cardiac Dysfunction in Patients with Chronic Kidney Disease.
Chinnappa S; Tu YK; Yeh YC; Glorieux G; Vanholder R; Mooney A
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30563136
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Translation of Microfluidic Transporter
van der Made TK; Fedecostante M; Scotcher D; Rostami-Hodjegan A; Sastre Toraño J; Middel I; Koster AS; Gerritsen KG; Jankowski V; Jankowski J; Hoenderop JGJ; Masereeuw R; Galetin A
Mol Pharm; 2019 Nov; 16(11):4551-4562. PubMed ID: 31525064
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis.
Jourde-Chiche N; Burtey S
Kidney Int; 2020 Jun; 97(6):1102-1104. PubMed ID: 32444090
[TBL] [Abstract][Full Text] [Related]
14. Role of Organic Anion Transporters in the Uptake of Protein-Bound Uremic Toxins by Human Endothelial Cells and Monocyte Chemoattractant Protein-1 Expression.
Favretto G; Souza LM; Gregório PC; Cunha RS; Maciel RAP; Sassaki GL; Toledo MG; Pecoits-Filho R; Souza WM; Stinghen AEM
J Vasc Res; 2017; 54(3):170-179. PubMed ID: 28472795
[TBL] [Abstract][Full Text] [Related]
15. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling.
Dubinsky S; Malik P; Hajducek DM; Edginton A
Clin Pharmacokinet; 2022 Jul; 61(7):997-1012. PubMed ID: 35508593
[TBL] [Abstract][Full Text] [Related]
16. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: Production pathway, challenges and recent advances in renal PBUTs clearance.
Daneshamouz S; Eduok U; Abdelrasoul A; Shoker A
NanoImpact; 2021 Jan; 21():100299. PubMed ID: 35559786
[TBL] [Abstract][Full Text] [Related]
17. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
18. Effects of nonsteroidal anti-inflammatory drugs on the renal excretion of indoxyl sulfate, a nephro-cardiovascular toxin, in rats.
Yu CP; Sweet DH; Peng YH; Hsieh YW; Chao PL; Hou YC; Lin SP
Eur J Pharm Sci; 2017 Apr; 101():66-70. PubMed ID: 28185988
[TBL] [Abstract][Full Text] [Related]
19. AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease.
Sivertsson E; Ceder S; Nangaku M; Hansell P; Nordquist L; Palm F
Kidney Blood Press Res; 2023; 48(1):114-123. PubMed ID: 36791683
[TBL] [Abstract][Full Text] [Related]
20. The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction.
Cunha RSD; Azevedo CAB; Falconi CA; Ruiz FF; Liabeuf S; Carneiro-Ramos MS; Stinghen AEM
Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
